Prognostic role of interleukin-6, interleukin-8, and leptin levels according to breast cancer subtype

Cancer Research and Treatment

Volumn 45, Issue 3, 2013, Pages 210-219

  Cho, Young Ae ^a   Sung, Mi Kyung ^b   Yeon, Jee Young ^b   Ro, Jungsil ^a   Kim, Jeongseon ^a  

^a National Cancer Center   (South Korea)

^b Sookmyung Women's University   (South Korea)

Author keywords

Breast neoplasms; Cytokines; Estrogen receptors; HER2; Progesterone receptors; Recurrence

Indexed keywords

ADIPONECTIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; KI 67 ANTIGEN; LAPATINIB; LEPTIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PROGESTERONE RECEPTOR; TAMOXIFEN; TRASTUZUMAB;

ADULT; ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CLINICAL FEATURE; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RECURRENCE FREE SURVIVAL; TRIPLE NEGATIVE BREAST CANCER;

EID: 84886312489     PISSN: 15982998     EISSN: 20059256     Source Type: Journal    
DOI: 10.4143/crt.2013.45.3.210     Document Type: Article

References (25)

1. Goldberg JE, Schwertfeger KL. Proinflammatory cytokines in breast cancer: mechanisms of action and potential targets for therapeutics. Curr Drug Targets. 2010;11:1133-1146.
2. Gilbert CA, Slingerland JM. Cytokines, obesity, and cancer: new insights on mechanisms linking obesity to cancer risk and progression. Annu Rev Med. 2013;64:45-57.
3. Nicolini A, Carpi A, Rossi G. Cytokines in breast cancer. Cytokine Growth Factor Rev. 2006;17:325-337.
4. Seruga B, Zhang H, Bernstein LJ, Tannock IF. Cytokines and their relationship to the symptoms and outcome of cancer. Nat Rev Cancer. 2008;8:887-899.
5. Onitilo AA, Engel JM, Greenlee RT, Mukesh BN. Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res. 2009; 7:4-13.
6. Gonzalez RM, Daly DS, Tan R, Marks JR, Zangar RC. Plasma biomarker profiles differ depending on breast cancer subtype but RANTES is consistently increased. Cancer Epidemiol Biomarkers Prev. 2011;20:1543-1551.
7. Levano KS, Jung EH, Kenny PA. Breast cancer subtypes express distinct receptor repertoires for tumor-associated macrophage derived cytokines. Biochem Biophys Res Commun. 2011;411:107-110.
8. Mcshane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, et al. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol. 2005;23:9067-9072.
9. Regitnig P, Reiner A, Dinges HP, Hofler G, Muller-holzner E, Lax SF, et al. Quality assurance for detection of estrogen and progesterone receptors by immunohistochemistry in Austrian pathology laboratories. Virchows Arch. 2002;441:328-334.
10. Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration- approved scoring system. J Clin Oncol. 1999;17:1983-1987.
11. Nam BH, Kim SY, Han HS, Kwon Y, Lee KS, Kim TH, et al. Breast cancer subtypes and survival in patients with brain metastases. Breast Cancer Res. 2008;10:R20.
12. Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol. 2010;11:174-183.
13. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. AJCC cancer staging manual. 7th ed. New York: Springer; 2010. p. 347-376.
14. Henson DE, Ries L, Freedman LS, Carriaga M. Relationship among outcome, stage of disease, and histologic grade for 22,616 cases of breast cancer. The basis for a prognostic index. Cancer. 1991;68:2142-2149.
15. Cole SW. Chronic inflammation and breast cancer recurrence. J Clin Oncol. 2009;27:3418-3419.
16. Salgado R, Junius S, Benoy I, Van Dam P, Vermeulen P, Van Marck E, et al. Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int J Cancer. 2003;103: 642-646.
17. Bachelot T, Ray-coquard I, Menetrier-caux C, Rastkha M, Duc A, Blay JY. Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients. Br J Cancer. 2003;88:1721-1726.
18. Benoy IH, Salgado R, Van Dam P, Geboers K, Van Marck E, Scharpe S, et al. Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin Cancer Res. 2004;10:7157-7162.
19. Muraro E, Martorelli D, Turchet E, Miolo G, Scalone S, Comaro E, et al. A different immunologic profile characterizes patients with HER-2-overexpressing and HER-2-negative locally advanced breast cancer: implications for immunebased therapies. Breast Cancer Res. 2011;13:R117.
20. Ciampricotti M, Vrijland K, Hau CS, Pemovska T, Doornebal CW, Speksnijder EN, et al. Development of metastatic HER2(+) breast cancer is independent of the adaptive immune system. J Pathol. 2011;224:56-66.
21. Barone I, Catalano S, Gelsomino L, Marsico S, Giordano C, Panza S, et al. Leptin mediates tumor-stromal interactions that promote the invasive growth of breast cancer cells. Cancer Res. 2012;72:1416-1427.
22. Catalano S, Marsico S, Giordano C, Mauro L, Rizza P, Panno ML, et al. Leptin enhances, via AP-1, expression of aromatase in the MCF-7 cell line. J Biol Chem. 2003;278:28668-28676.
23. Catalano S, Mauro L, Marsico S, Giordano C, Rizza P, Rago V, et al. Leptin induces, via ERK1/ERK2 signal, functional activation of estrogen receptor alpha in MCF-7 cells. J Biol Chem. 2004;279:19908-19915.
24. Garofalo C, Koda M, Cascio S, Sulkowska M, Kanczuga-koda L, Golaszewska J, et al. Increased expression of leptin and the leptin receptor as a marker of breast cancer progression: possible role of obesity-related stimuli. Clin Cancer Res. 2006; 12:1447-1453.
25. Karczewska A, Nawrocki S, Breborowicz D, Filas V, Mackiewicz A. Expression of interleukin-6, interleukin-6 receptor, and glycoprotein 130 correlates with good prognoses for patients with breast carcinoma. Cancer. 2000;88:2061-2071.